Endometriosis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Endometriosis - Pipeline Review, H2 2016

Endometriosis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Endometriosis - Pipeline Review, H2 2016
Published Sep 14, 2016
132 pages — Published Sep 14, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Endometriosis - Pipeline Review, H2 2016, provides an overview of the Endometriosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Endometriosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Endometriosis
- The report reviews pipeline therapeutics for Endometriosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Endometriosis therapeutics and enlists all their major and minor projects
- The report assesses Endometriosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Endometriosis


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Endometriosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics
- Develop an

  
Source:
Document ID
GMDHC8457IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents28
  List of Tables81
  List of Figures91
Introduction101
  Global Markets Direct Report Coverage101
Endometriosis Overview111
Therapeutics Development122
  Pipeline Products for Endometriosis Overview121
  Pipeline Products for Endometriosis Comparative Analysis131
Endometriosis Therapeutics under Development by Companies142
Endometriosis Therapeutics under Investigation by Universities/Institutes161
Endometriosis Pipeline Products Glance174
  Late Stage Products171
  Clinical Stage Products181
  Early Stage Products191
  Unknown Stage Products201
Endometriosis Products under Development by Companies213
Endometriosis Products under Investigation by Universities/Institutes241
Endometriosis Companies Involved in Therapeutics Development2523
  AbbVie Inc251
  Addex Therapeutics Ltd261
  APAvadis Biotechnologies Srl271
  Astellas Pharma Inc.281
  Bayer AG291
  Dongkook Pharmaceutical Co., Ltd.301
  ElexoPharm GmbH311
  EndoCeutics, Inc.321
  Enteris BioPharma, Inc.331
  Euroscreen S.A.341
  Evotec AG351
  Forendo Pharma Limited361
  GlaxoSmithKline Plc371
  Kissei Pharmaceutical Co., Ltd.381
  Lipicard Technologies Limited391
  Luye Pharma Group Ltd.401
  Nippon Shinyaku Co., Ltd.411
  Orphagen Pharmaceuticals, Inc.421
  Philogen S.p.A.431
  Repros Therapeutics Inc.441
  SK Chemicals Co., Ltd.451
  Takeda Pharmaceutical Company Limited461
  ValiRx Plc471
Endometriosis Therapeutics Assessment4812
  Assessment by Monotherapy Products481
  Assessment by Combination Products491
  Assessment by Target503
  Assessment by Mechanism of Action533
  Assessment by Route of Administration562
  Assessment by Molecule Type582
Drug Profiles6059
  acolbifene hydrochloride + GnRH Agonist + prasterone Drug Profile601
  ASP-1707 Drug Profile611
  BAY-1128688 Drug Profile621
  bentamapimod Drug Profile631
  Drug to Inhibit C-Jun for Endometriosis Drug Profile641
  Drugs for Endometriosis Drug Profile651
  Drugs for Endometriosis and Uterine Fibroids Drug Profile661
  elagolix sodium Drug Profile674
  epelsiban besylate Drug Profile712
  ESN-364 Drug Profile732
  EVE-104 Drug Profile751
  FP-5677 Drug Profile761
  goserelin biosimilar Drug Profile771
  goserelin ER Drug Profile781
  KLH-2109 Drug Profile791
  leuprolide acetate Drug Profile801
  LT-6121 Drug Profile811
  MIA-602 Drug Profile821
  Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis Drug Profile831
  NS-580 Drug Profile841
  Peptides for Endometriosis and Hepatic Tumor Drug Profile851
  Peptides to Inhibit Aminopeptidase A for Endometriosis and Hepatic (Liver) Tumor Drug Profile861
  PGL-2001 Drug Profile871
  Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome Drug Profile881
  relugolix Drug Profile892
  SKI-2670 Drug Profile911
  Small Molecule to Antagonize FSH Receptor for Women's Health Drug Profile921
  Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology Drug Profile931
  Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis Drug Profile941
  Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease Drug Profile951
  Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis Drug Profile961
  Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers Drug Profile971
  Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis Drug Profile981
  SR-16234 Drug Profile991
  Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology Drug Profile1001
  telapristone acetate Drug Profile1018
  Tetravil Drug Profile1092
  triptorelin biosimilar Drug Profile1111
  VAL-201 Drug Profile1124
  vilaprisan Drug Profile1161
  VPE-001 Drug Profile1171
  VPEA-004 Drug Profile1181
Endometriosis Dormant Projects1192
Endometriosis Discontinued Products1211
Endometriosis Product Development Milestones1229
  Featured News &Press Releases1221
    Aug 05, 2016: Evotec Achieves Clinical Development Milestone as Part of Its Multi-Target Alliance with Bayer in Endometriosis1221
    Jul 06, 2016: ObsEva Receives Clearance from US FDA to Initiate Phase 2b Study EDELWEISS with OBE2109, a Potentially Best-in-Class Oral GnRH Antagonist, for the Treatment of Endometriosis1221
    Mar 31, 2016: ValiRx is exhibiting and presenting at the prestigious AACR1231
    Feb 10, 2016: AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis1231
    Dec 21, 2015: Repros Updates Proellex Program1241
    Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on Vilaprisan at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA1241
    Feb 26, 2015: New Endometriosis Patent Grant for ValiRx1251
    Jan 15, 2015: Clinical Trial and Development Update on VAL201 for oncology indications1261
    Jan 08, 2015: Abbvie Announces Positive Top-Line Results From Phase 3 Study Of Investigational Medicine Elagolix In Patients With Endometriosis1261
    Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting1271
    Apr 01, 2014: ValiRx Provides Updated On Anti-cancer Therapeutic VAL2011281
    Mar 13, 2014: New drug candidate showed efficacy in human endometriosis samples1281
    Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN3641281
    Oct 03, 2013: ValiRx Files Phase IB/dose escalation study for VAL2011291
    Aug 29, 2013: Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis1292
Appendix1312
  Methodology1311
  Coverage1311
  Secondary Research1311
  Primary Research1311
  Expert Panel Validation1311
  Contact Us1311
  Disclaimer1321

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Endometriosis - Pipeline Review, H2 2016" Sep 14, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Endometriosis-Pipeline-Review-H2-2016-2088-16542>
  
APA:
Global Markets Direct - Market Research. (2016). Endometriosis - Pipeline Review, H2 2016 Sep 14, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Endometriosis-Pipeline-Review-H2-2016-2088-16542>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.